Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesEfficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries
European Journal of Neurology, 07/13/09
Putzki N et al. - Natalizumab has been recommended for the treatment of relapsing–remitting multiple sclerosis (RRMS) in patients with insufficient response to interferon-beta/glatiramer acetate (DMT) or aggressive MS. Natalizumab is effective after insufficient response to other DMT and also in patients with high disease activity.
Related Articles
Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
Multiple Sclerosis, 10/09/09
Relevance Score: 87%
Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
Multiple Sclerosis, 10/26/09
Relevance Score: 84%
Targeted Therapies in Inflammatory Bowel Disease
Digestive Diseases, 11/11/09
Relevance Score: 82%
Treatment of multiple sclerosis: role of natalizumab
Neurological Sciences, 11/18/09
Relevance Score: 80%
Multiple sclerosis. Part 2: Ophthalmic issues in MS therapy
Current Opinion in Ophthalmology, 10/29/09
Relevance Score: 80%
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Micro-ribonucleic acid profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain, 12/04/09
Dysregulated Epstein-Barr virus infection in patients with CIDP
Journal of Neuroimmunology, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09
Health related quality of life in early Parkinson's disease: Impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort
Parkinsonism & Related Disorders, 12/04/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/04/09
Sponsor
Article Search
Sponsor